Skip to main content

Sanofi Ventures — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

72
Companies
$3.6B
Total invested
$71.3M
Avg. check
14
Industries
Biotechnology 21Health Care 12Pharmaceutical 12Therapeutics 11Medical 11Life Science 5+8 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 72
i2o Therapeutics
August 2023

I2o Therapeutics is a biotech company that develops safe and effective oral formulations of therapies.

Biotechnology · Allston$46.0M Series A
Tisento Therapeutics
July 2023

Tisento Therapeutics is a MA-based developer of novel medicines to treat diseases with significant unmet medical needs.

Health Care · Cambridge$81.0M Series A
OMass Therapeutics
May 2023

OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics.

Life Science · Oxford$12.5M Series B
Muna Therapeutics
January 2026

Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.

Biopharma · Copenhagen$1.0M Grant
Atalanta Therapeutics
January 2025

Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.

Biotechnology · Boston$97.0M Series B
Escient Pharmaceuticals
November 2022

Escient Pharmaceuticals is a privately-held biotechnology company focusing on the advancement of G Protein-Coupled Receptor targeted drugs.

Biotechnology · San Diego$120.0M Series C
Lifordi Immunotherapeutics
November 2025

Lifordi Immunotherapeutics is a biotech company that provides antibody-drug conjugates for autoimmune and inflammatory disorders.

Biotechnology · Burlington$42.0M Venture - Series Unknown
T-Therapeutics
November 2025

T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge.

Biotechnology · Cambridge$32.0M Series A
Zag Bio
October 2025

Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases.

Biopharma · Cambridge$80.0M Series A
Dice Therapeutics
October 2022

Dice Therapeutics is a clinical-stage biopharmaceutical company that makes medicines for chronic autoimmune and inflammatory diseases.

Biotechnology · San Francisco$345.0M Post-IPO Equity
Matchpoint Therapeutics
October 2022

Matchpoint Therapeutics is a biotechnology company that integrates chemoproteomics, ML, and covalent chemistry to treat serious illnesses.

Biotechnology · Cambridge$70.0M Series A
QuantX Biosciences
February 2026

QuantX Biosciences is a biotechnology company that specializes in computational drug discovery and small-molecule therapeutic products.

Biotechnology · Princeton$85.0M Series B
Imbria Pharmaceuticals
November 2025

Imbria Pharmaceuticals is a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases.

Biotechnology · BostonSeries B
Expedition Therapeutics
October 2025

Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases.

Biotechnology · San Francisco$165.0M Series A
QuantHealth
October 2025

Quant Health offers drug simulation, computational biology, clinical data science, respiratory, trial simulation, and oncology services.

Artificial Intelligence (AI) · Tel AvivSeries Unknown
ReCode Therapeutics
September 2025

ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics.

Biopharma · Dallas$29.4M Debt Financing
Splice Bio
June 2025

Splice Bio develops gene therapies using its Protein Splicing platform for genetic diseases.

Biotechnology · Barcelona$135.0M Series B
Therini Bio
May 2025

Therini Bio specializes in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases.

Biotechnology · San Francisco$39.0M Series A
Eligo Bioscience
May 2025

Eligobiotics provides a new approach to explore, understand, and control bacterial ecosystems both in human and animals.

Biotechnology · Paris$5.0M Grant
Granite Bio
April 2025

Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.

Biotechnology · Basel$70.0M Series B
Glycomine
April 2025

Glycomine is an early-stage biotech working on replacement therapies for rare diseases.

Biotechnology · San Carlos$115.0M Series C
AdvanCell
April 2025

AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer treatment.

Biotechnology · Sydney$11.3M Grant
Click Therapeutics
March 2025

Click Therapeutics develops software as a medical treatment prescription platform designed to deliver digital treatments for patients.

Biotechnology · New York$48.6M Series C
Curevo
March 2025

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.

Biopharma · Bothell$110.0M Series B

Where Sanofi Ventures invests

Biotechnology21
Health Care12
Pharmaceutical12
Therapeutics11
Medical11
Life Science5

About Sanofi Ventures's portfolio

How many companies has Sanofi Ventures invested in?

Sanofi Ventures has invested in 72 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Sanofi Ventures invest in?

Sanofi Ventures's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Therapeutics, Medical. The firm invests across 14 different industry categories.

What is Sanofi Ventures's largest investment?

Among tracked funding rounds, Dice Therapeutics received $345.0M in a Post-IPO Equity round. Sanofi Ventures's total known invested capital is $3.6B.

What is the average investment size for Sanofi Ventures?

Sanofi Ventures's average investment size is $71.3M across its portfolio of 72 companies.

What are Sanofi Ventures's most recent investments?

Recent Sanofi Ventures portfolio additions include i2o Therapeutics, Tisento Therapeutics, OMass Therapeutics, Muna Therapeutics, Atalanta Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 72 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →